Literature DB >> 1171986

4-Trifluoromethylimidazoles and 5-(4-pyridyl)-1,2,4-triazoles, new classes of xanthine oxidase inhibitors.

J J Baldwin, P A Kasinger, F C Novello, J M Sprague, D E Duggan.   

Abstract

The syntheses of a number of 2-substituted 4-trifluoromethylimidazoles and 3-substituted 5-(4-pyridyl)-1,2,4-triazoles are described. The trifluoromethylimidazoles were prepared from 3,3-dibromo-1,1,1-trifluoroacetone after hydrolysis with aqueous sodium acetate solution and condensation with an aldehyde in the presence of ammonia. Basic hydrolysis of the trifluoromethyl group was found to provide a facile method for the synthesis of imidazole-4-carboxylic acids. In the imidazole series a 2-aryl substituent and a free imino group were required for xanthine oxidase inhibitory activity. The triazoles were obtained through the reaction of an aroylhydrazine and an imino ether followed by thermal ring closure of the intermediate acylamidrazone. As in the imidazole series, a free imino group is an absolute requirement for in vitro activity. Additional structure-activity relationships of these compounds are presented.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1171986     DOI: 10.1021/jm00243a007

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  4 in total

1.  Discovery of RAF265: A Potent mut-B-RAF Inhibitor for the Treatment of Metastatic Melanoma.

Authors:  Teresa E Williams; Sharadha Subramanian; Joelle Verhagen; Christopher M McBride; Abran Costales; Leonard Sung; William Antonios-McCrea; Maureen McKenna; Alicia K Louie; Savithri Ramurthy; Barry Levine; Cynthia M Shafer; Timothy Machajewski; Paul A Renhowe; Brent A Appleton; Payman Amiri; James Chou; Darrin Stuart; Kimberly Aardalen; Daniel Poon
Journal:  ACS Med Chem Lett       Date:  2015-08-03       Impact factor: 4.345

2.  Antihypertensive and other cardiovascular effects of 2-(3-pyridyl)- and 2-(4-pyridyl)-4-trifluoromethylimidazoles.

Authors:  A Scriabine; C T Ludden; L S Watson; J M Stavorski; G Morgan; J J Baldwin
Journal:  Experientia       Date:  1979-05-15

3.  Selective Inhibition of Collagen Prolyl 4-Hydroxylase in Human Cells.

Authors:  James D Vasta; Kristen A Andersen; Kathryn M Deck; Christopher P Nizzi; Richard S Eisenstein; Ronald T Raines
Journal:  ACS Chem Biol       Date:  2015-11-19       Impact factor: 5.100

Review 4.  Mechanistic insights into xanthine oxidoreductase from development studies of candidate drugs to treat hyperuricemia and gout.

Authors:  Takeshi Nishino; Ken Okamoto
Journal:  J Biol Inorg Chem       Date:  2014-12-12       Impact factor: 3.358

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.